NASDAQ:EYEN Eyenovia (EYEN) Stock Price, News & Analysis $0.49 -0.02 (-3.89%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.47▼$0.5450-Day Range$0.47▼$1.4452-Week Range$0.37▼$2.57Volume1.32 million shsAverage Volume1.27 million shsMarket Capitalization$26.61 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Eyenovia alerts: Email Address Eyenovia MarketRank™ Stock AnalysisAnalyst RatingBuy3.33 Rating ScoreUpside/Downside1,924.3% Upside$10.00 Price TargetShort InterestBearish5.62% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.04 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.59) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector602nd out of 910 stocksPharmaceutical Preparations Industry278th out of 426 stocks 3.7 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyenovia has only been the subject of 2 research reports in the past 90 days.Read more about Eyenovia's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.62% of the outstanding shares of Eyenovia have been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently increased by 11.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYEN. Previous Next 1.2 News and Social Media Coverage News SentimentEyenovia has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eyenovia this week, compared to 2 articles on an average week.Search InterestOnly 25 people have searched for EYEN on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,042,577.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.10% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 25.84% of the stock of Eyenovia is held by institutions.Read more about Eyenovia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to grow in the coming year, from ($0.59) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Eyenovia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Eyenovia Stock (NASDAQ:EYEN)Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Read More EYEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYEN Stock News HeadlinesAugust 29, 2024 | insidertrades.comEyenovia, Inc. (NASDAQ:EYEN) CEO Michael M. Rowe Buys 27,071 SharesAugust 28, 2024 | insidertrades.comEyenovia, Inc. (NASDAQ:EYEN) CEO Michael M. Rowe Buys 50,000 SharesSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 5 at 7:00 AM | globenewswire.comEyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.September 3, 2024 | globenewswire.comEyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial OfficerAugust 30, 2024 | americanbankingnews.comMichael M. Rowe Buys 50,000 Shares of Eyenovia, Inc. (NASDAQ:EYEN) StockAugust 28, 2024 | americanbankingnews.comEyenovia, Inc. (NASDAQ:EYEN) to Post Q3 2024 Earnings of ($0.10) Per Share, Brookline Capital Management ForecastsAugust 23, 2024 | globenewswire.comEyenovia Announces Closing of Public OfferingSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 22, 2024 | benzinga.comWhy Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?August 21, 2024 | markets.businessinsider.comEyenovia Prices 12.85 Mln Shares At $0.40/Share; Stock TanksAugust 21, 2024 | msn.comWhy Eyenovia (EYEN) Stock Is Getting Hammered TodayAugust 21, 2024 | globenewswire.comEyenovia Announces Pricing of $5.14 Million Public OfferingAugust 20, 2024 | globenewswire.comEyenovia, Inc. Announces Proposed Public OfferingAugust 16, 2024 | ca.finance.yahoo.comEyenovia, Inc. (EYEN) Latest Stock News & Headlines - Yahoo FinanceAugust 15, 2024 | finanznachrichten.deEyenovia, Inc.: Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | msn.comEyenovia, Inc. (NASDAQ:EYEN) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | finance.yahoo.comEyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceSee More Headlines Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EYEN CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,924.3%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,260,000.00 Net Margins-116,506.25% Pretax Margin-116,506.23% Return on Equity-547.46% Return on Assets-121.89% Debt Debt-to-Equity Ratio3.72 Current Ratio0.46 Quick Ratio0.27 Sales & Book Value Annual Sales$31,405.00 Price / Sales847.39 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-12.35Miscellaneous Outstanding Shares53,871,000Free Float50,046,000Market Cap$26.61 million OptionableOptionable Beta1.74 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Tsontcho Ianchulev M.D. (Age 50)M.P.H., MPH, Co-Founder & Executive Chairman Comp: $167.5kMr. Michael M. Rowe (Age 62)CEO & Director Comp: $775.47kMr. John P. Gandolfo CPA (Age 63)CFO & Secretary Comp: $578.15kMr. Bren Kern (Age 43)COO & Corporate VP Comp: $415.58kAlexander LoboInvestor ContactKey CompetitorsMarker TherapeuticsNASDAQ:MRKRCervoMedNASDAQ:CRVOElutiaNASDAQ:ELUTMediciNovaNASDAQ:MNOVAnixa BiosciencesNASDAQ:ANIXView All CompetitorsInsiders & InstitutionsMichael M RoweBought 27,071 shares on 8/28/2024Total: $14,076.92 ($0.52/share)Michael M RoweBought 50,000 shares on 8/26/2024Total: $28,500.00 ($0.57/share)SkyView Investment Advisors LLCBought 146,071 shares on 8/16/2024Ownership: 0.271%Armistice Capital LLCBought 6,060,606 shares on 8/15/2024Ownership: 11.250%Point72 Asia Singapore Pte. Ltd.Bought 43,784 shares on 8/15/2024Ownership: 0.081%View All Insider TransactionsView All Institutional Transactions EYEN Stock Analysis - Frequently Asked Questions How have EYEN shares performed this year? Eyenovia's stock was trading at $2.08 on January 1st, 2024. Since then, EYEN stock has decreased by 76.3% and is now trading at $0.4940. View the best growth stocks for 2024 here. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) announced its earnings results on Monday, August, 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.38 million. Eyenovia had a negative net margin of 116,506.25% and a negative trailing twelve-month return on equity of 547.46%. When did Eyenovia IPO? Eyenovia (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO. Who are Eyenovia's major shareholders? Top institutional shareholders of Eyenovia include Armistice Capital LLC (11.25%), SkyView Investment Advisors LLC (0.27%), Nations Financial Group Inc. IA ADV (0.09%) and Ground Swell Capital LLC (0.08%). Insiders that own company stock include Stuart M Grant, Tsontcho Ianchulev, Michael M Rowe, Charles E Iv Mather, Ellen R Strahlman and Bren Kern. View institutional ownership trends. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX) and Trevena (TRVN). This page (NASDAQ:EYEN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
